The use of VP-16 for stem cell mobilization has been cited as a significant risk factor for the development of therapy-related myelodysplasia/leukemia (tMDS/tAML) following autologous transplantation. The present study analyzed a large cohort of patients who underwent autotransplantation following stem cell mobilization with VP-16 and radiation-free preparation in order to determine the risk of tMDS/tAML. The estimated incidence of 9.9% at 7 years suggests that in the absence of TBI, VP-16 priming is not associated with an increased incidence of tMDS/tAML.
Therapy-related myelodysplasia (tMDS) and acute leukemia (tAML) occur in up to 15% of patients following autotransplantation.
1-7 Risk factors include older age, prior fludarabine, mechlorethamine, or chlorambucil therapy, prior radiotherapy, and lower doses of infused progenitor cells. [1] [2] [3] [4] [5] [6] [7] [8] The inclusion of total body irradiation (TBI), particularly 413.2 Gy, in the transplant preparative regimen has also been identified as a risk factor. [4] [5] [6] [7] [8] Krishnan et al 9 reported that stem cell mobilization with VP-16 is a significant risk factor for the development of tMDS/tAML following transplantation for Hodgkin's disease and non-Hodgkin's lymphoma, dampening enthusiasm for this priming method. Most of the patients in that study received transplantation conditioning with TBI. In order to determine the risk following VP-16 priming and radiation-free preparative therapy, we analyzed the largest reported cohort of such patients.
Patients and methods
From January 1992 through May 2001, 480 consecutive patients with non-Hodgkin's lymphoma (NHL) (n ¼ 153), Hodgkin's disease (n ¼ 71), or breast cancer (n ¼ 256) underwent mobilization of peripheral blood progenitor cells with 2 g/m 2 of VP-16 and 5 mg/kg daily of G-CSF as previously described. 10 Survivors were followed for a minimum of 18 months after transplantation. All NHL and Hodgkin's patients underwent preparation for transplantation with busulfan (14 or 16 mg/kg, respectively) and cyclophosphamide (120 mg/kg) with (n ¼ 209) or without VP-16 (n ¼ 15), 11 and breast cancer patients with thiotepa, carboplatin, and cyclophosphamide (STAMP V, n ¼ 256). Marrow examination with cytogenetic analysis was routinely performed prior to transplantation.
Results
The median age was 46 years (range 14-72 years). There were no patients with abnormal cytogenetic analysis prior to BMT identified. The median follow up for surviving patients exceeds 36 months (range 18-124 months) and 63 patients were surviving for more than 5 years at the time of analysis. Data was analyzed as of December 1, 2002. In this cohort, five of 480 of patients who received priming with VP-16 developed tMDS or tAML. Two patients developed myelodysplastic syndrome (MDS) 5.5 and 7.5 years following autotransplantation for Hodgkin's disease and one patient developed MDS 6.5 years following transplantation for breast cancer. The fourth and fifth developed AML 1 year following transplantation for non-Hodgkin's lymphoma and 3.5 years following transplant for Hodgkin's. Four of the five had received local radiation therapy prior to or immediately following transplantation. All four patients with Hodgkin's or NHL who developed tMDS received VP-16 as part of this preparative regimen. No patient developed an 11q23 abnormality; two had cytogenetic abnormalities (one with 5q-, another with multiple abnormalities). The estimated incidence of developing tMDS or tAML in this analysis is 9.9% (95% CI 0-19.9%) at 7 years (Figure 1 ). For patients with NHL or Hodgkin's disease, the incidence is 10.0% (95% CI: 0-22.5%) at 7 years (Figure 2 ).
Discussion
The administration of VP-16 followed by daily G-CSF is an effective and safe method for mobilization of peripheral stem cells. In addition, it is an active regimen in the treatment of Hodgkin's and non-Hodgkin's lymphoma. 10 The assertion that VP-16 mobilization is associated with an increased risk of tMDS/tAML 9 has limited its application, although other studies have not detected it as a risk factor. 8 In Krishnan's analysis of 61 patients, who received priming with VP-16, three developed tAML, all with 11q23 cytogenetic abnormalities. 9 Although there was a slightly greater incidence of tMDS/tAML in the patients who received priming with VP-16 than in those patients who did not receive priming with VP-16, these incidence rates were not significantly different. A multivariable survival analysis using Cox proportional hazards indicated a significant increase in the risk of developing tMDS or tAML for those patients who received VP-16 priming. The model assumes that the relative risk of developing tMDS/tAML is constant over time. It has previously been established that patients develop tMDS/tAML following VP-16 with a much shorter latency period than following alkylating agents and other treatments, 12 suggesting that this model may not be valid. Further, of the 61 patients who received priming with VP-16, 43 patients received TBI. It is not stated whether the three patients who developed AML received TBI. Other data suggest a potential interaction between TBI and VP-16. Analysis of 493 patients with NHL who underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation identified only TBI, when used in combination with etoposide for transplant conditioning, as a significant risk factor for the development of tMDS/tAML. 13 The small number of events is also of concern, as is the number of patients receiving VP-16 for mobilization in studies which did not detect it as a risk factor. 8 The present study analyzed a large cohort of patients receiving VP-16 for stem cell mobilization with median follow-up longer than the median time to VP-16-related tMDS/tAML. This present study demonstrates an incidence of tMDS/tAML similar to that seen in other studies and no cases of 11q23 cytogenetic abnormalities. Thus, in the absence of TBI, no increased risk for tMDS/tAML is identified with VP-16 mobilization. VP-16 is an efficient and appropriate method of mobilization. A large prospective randomized study of patients mobilized with and without VP-16 and conditioned with and without TBI would be required to determine the influence of TBI on the incidence of tMDS/tAML following VP-16 mobilization. Therapy-related myelodysplasis and leukemia E Copelan et al
